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1
. The clinical management of patients with brain cancers relies heavily on non-invasive imaging because the anatomical location of these cancers can often prohibit tumour sampling and/or surgical resection. MRI, with or without contrast enhancement, remains the standard approach for the initial imaging evaluation of patients with suspected brain cancer. MRI can also be used to guide tissue biopsy sampling in order to establish a diagnosis, to assess disease progression or to monitor for recurrences, and to evaluate the effectiveness of therapies.
We have made major advances in understanding the pathology and biology of primary brain tumours; nevertheless, considerable work is needed to determine how this knowledge can be exploited to develop non-invasive imaging modalities that guide the diagnosis, treatment, and follow-up monitoring of patients with brain cancer. In the era of personalized medicine, we are beginning to appreciate the genetic complexity of primary brain tumours. This information can open novel therapeutic windows by enabling the identification of actionable targets and the development of corresponding molecularly targeted therapies. Challenges remain, however, in identifying, stratifying, and monitoring patients using advanced imaging technologies, and in leveraging the information gathered from genomics and other 'omics' approaches to develop molecular imaging modalities.
The field of cancer metabolism provides the best example of the use of molecular imaging in the clinical management of patients with cancer. Altered tumour metabolism can be imaged using two principal techniques. Firstly, PET imaging, which is based on labelling of biological substrates with radionuclides, such as 11 C or 18 F. PET imaging is highly sensitive, enabling 1 Abstract | The revolution in cancer genomics has uncovered a variety of clinically relevant mutations in primary brain tumours, creating an urgent need to develop non-invasive imaging biomarkers to assess and integrate this genetic information into the clinical management of patients. Metabolic reprogramming is a central hallmark of cancer, including brain tumours; indeed, many of the molecular pathways implicated in the pathogenesis of brain tumours result in reprogramming of metabolism. This relationship provides the opportunity to devise in vivo metabolic imaging modalities to improve diagnosis, patient stratification, and monitoring of treatment response. Metabolic phenomena, such as the Warburg effect and altered mitochondrial metabolism, can be leveraged to image brain tumours using techniques including PET and MRI. Moreover, genetic alterations, such as mutations affecting isocitrate dehydrogenase, are associated with unique metabolic signatures that can be detected using magnetic resonance spectroscopy. The need to translate our understanding of the molecular features of brain tumours into imaging modalities with clinical utility is growing; metabolic imaging provides a unique platform to achieve this objective. In this Review, we examine the molecular basis for metabolic reprogramming in brain tumours, and examine current non-invasive metabolic imaging strategies that can be used to interrogate these molecular characteristics with the ultimate goal of guiding and improving patient care.
low concentrations of radiolabelled substrates to be detected using this technique. The molecular sensitivity -or the limit of signal detection -in standard systems is 10 −11 to 10 −12 mol/l with a required molecular probe mass of 1-100 ng, and is a composite variable influenced by the properties of the molecular probe; tissue physiology and biology; and the signal sensitivity, spatial resolution, and contrast resolution of the imaging system 2 . In general, most cancer cells generate ATP predominantly by anaerobic metabolism of glucose to lactate in the cytoplasm, even in the presence of oxygen levels that would support further aerobic mitochondrial metabolism -a phenomenon termed the 'Warburg effect' . Although this metabolic phenotype enables cancer cells to generate ATP rapidly, the number of ATP mol ecules produced per mole of glucose is much lower than that produced by mitochondrial metabolism, thereby increasing the glucose demand of cancer cells 3 . Thus, the most common form of PET imaging in oncology takes advantage of this high glucose demand resulting from the Warburg effect, and involves the use of an 18 F-labelled glucose-analogue tracer, 2-[
18 F]fluoro-2-deoxy-d-glucose ( 18 F-FDG). This glucose analogue cannot be metabolized further than initial phosphorylation by hexokinase and, therefore, accumulates in cells, providing an indication of their glucose demand. Singlevoxel magnetic resonance spectroscopy (MRS) and multi-voxel magnetic resonance spectroscopic imaging (MRSI) are other techniques that enable detailed interrogation of cellular metabolic activity. Specifically, these modalities involve the characterization of the chemical and molecular composition of the tumour and the tumour microenvironment, in comparison with nonmalignant tissues, based on radiofrequency signals generated by nuclear spins of magnetic-resonance-active nuclei, including 1 H, 31 P, and 13 
C (REF. 4).
Importantly, the capacity of oncogenes to directly reprogramme cellular metabolism, which enables tumour cells to survive, grow, and proliferate, is emerging as a fundamental concept in cancer biology 5, 6 . Many oncogenes that are expressed in brain tumours influence specific metabolic pathways, including glucose, amino acid, and fatty acid metabolism. In this Review, we evaluate the genomic revolution in brain tumour biology, describe the rewiring of metabolic pathways in cancer cells that results from these genetic alterations, and discuss the translation of metabolic reprogramming into non-invasive tumour imaging in patients.
Genomic heterogeneity of glial tumours
The 2016 update of the WHO Classification of Tumours of the Central Nervous System 1 defines two major groups of glial tumours: astrocytic tumours and oligodendroglial tumours. Additionally, histological criteria are used to define tumour grade -low grade (grade I and grade II) and high grade (grade III, grade IV GBM). Glial tumours in adults and children are morphologically comparable and have historically been considered to have a similar biology; however, next-generation sequencing (NGS) studies have revealed that, strikingly, gliomas in adults and children are genetically distinct. This observation prompted the WHO to incorporate molecular characteristics, such as driver mutational status, together with the histological type and tumour grade into their revised classification system, in the form of an integrated diagnosis 1 . In adults, >90% of GBMs harbour genetic alterations that converge on the PI3K/AKT/mTOR pathway, including enhanced activation of receptor tyrosine kinases that transmit signals via this pathway, such as EGFR (which occurs in ~60% of patients), PDGFRA (in ~10%), FGFR (in ~3%) and MET (in ~1%) 7, 8 . Other genetic alterations in this pathway that are present in GBMs include PTEN deletion (which is detected in ~40% of patients) and mutations in PIK3CA, which encodes the catalytic subunit of PI3K (in ~20%) 1, 7, 8 (TABLE 1) . Thus, the PI3K/AKT/mTOR pathway is one of the primary drivers of adult GBM. By contrast, high-grade gliomas in children are characterized by mutations that result in epigenetic reprogramming: histone H3 K27M and G34R/V mutations are detected in ~60% of paediatric patients with GBMs (TABLE 1) , and histone H3 K27M mutations occur in >80% of pontine (termed diffuse intrinsic pontine gliomas) and midline (brain-stem and thalamus) gliomas 1, [9] [10] [11] [12] . Similarly, low-grade gliomas in adults and children, although similar histologically, have different genetic drivers. More than 70% of intermediate-grade (grade II and III) gliomas in adults, including astrocytomas and oligodendrogliomas, harbour mutations in isocitrate dehydrogenase 1 or 2 (IDH1/2; TABLE 1). IDH1/2-mutant gliomas tend to occur in younger adults with a mean patient age at diagnosis of 38 years and are associated with a favourable prognosis relative to their IDH1/2-wildtype counterparts 1, 13 . IDH1/2-mutant gliomas that progress to GBM are classified as secondary GBMs (TABLE 1) ; these IDH1/2-mutant tumours constitute ~5% of GBMs in adults, and have a favourable prognosis compared with IDH1/2-wild-type GBMs . Low-grade gliomas that occur predominantly in children and young adults often have constitutive activation of BRAF (TABLE 1) . In particular, fusion of the kinase domain of BRAF with the protein KIAA1549 is an oncogenic alteration that is present in 30-70% of pilocytic astrocytomas (with a higher frequency in cere bellar tumours compared with cortical tumours) 1, 14 . Similarly, activating BRAF point mutations (generating BRAF V600E, for example) are detected at a high frequency in other low-grade brain tumours in paediatric patients, such as pleomorphic xanthoastrocytomas (70%) and gangliogliomas (20%), and at lower
Key points
• Brain tumours, such as gliomas, in adults and children are morphologically similar, but harbour different genomic alterations, both across and within histological subtypes, that affect prognosis and treatment response • Many of these genomic alterations lead to reprogramming of cellular metabolism, including glucose, amino acid, and lipid metabolism • The metabolic reprogramming in brain tumours can be visualized and assessed using various non-invasive clinical imaging modalities • Metabolic imaging shows great promise as a means to non-invasively evaluate some of the genomic alterations in order to guide the clinical management of patients frequencies in pilocytic astrocytomas and diffuse astrocytomas 1, 14 . Thus, the genetic drivers of childhood and adult gliomas are distinctly different.
Precision medicine for brain tumours
The subclassification of brain tumours into distinct groups that can inform the clinical management of patients, beyond what is possible based on analyses of histological grade alone, is another important development arising from molecular studies of these tumours.
For example, grade IV medulloblastomas, which are predominantly paediatric tumours, can be classified into four molecular subtypes: Sonic Hedgehog (SHH), WNT, Group 3, and Group 4 (REFS 1, 15, 16) (TABLE 1) . Similarly, adult GBMs can be subdivided into two categories: primary, IDH-wild-type GBMs; and secondary, IDH-mutant GBMs 1 (TABLE 1) .
Indeed, NGS studies have refined our understanding of brain tumours and our approach to caring for both adults and paediatric patients with brain cancer. In 17 . Similarly, inhibition of BRAF V600E using vemurafenib is efficacious in paediatric patients with BRAF
V600E
-mutant brain tumours [18] [19] [20] . Moreover, pharmacological inhibitors of mutant IDH1 have shown promise in animal models of IDH1-mutant, but not in IDH1-wild-type, glioma 21 . Thus, integrating the molecular characteristics of brain tumours into therapeutic decision-making is increasingly integral to patient management. In the clinic, the molecular features of brain cancers are currently assessed using tissue samples obtained using tumour biopsy or resection. Importantly, however, obtaining such samples is not always feasible for some brain tumours, such as pontine and brainstem tumours, owing to surgical challenges relating to the tumour location. Furthermore, the direct evaluation of the effectiveness of targeted therapies via longitudinal assessment of serial samples is not practical owing to difficulties in performing repeated biopsies. Conventional MRI, the current standard imaging modality for visualization of brain tumours, is inadequate for evaluation of molecular alterations. Thus, non-invasive, metabolic imaging of brain tumours is now emerging as a means to assess some of these molecular and metabolic alterations.
Oncogenic reprogramming of metabolism

Imaging glucose metabolism
Glucose is metabolized into pyruvate by glycolysis in the cytoplasm (FIG. 1) . Under aerobic conditions, pyruvate can be oxidized to acetyl-coenzyme A (acetyl-CoA), which can enter the mitochondrial tricarboxylic acid (TCA) cycle (FIG. 2) , fueling ATP production via oxidative phosphorylation. Brain tumours typically exhibit the Warburg effect, whereby pyruvate is diverted away from the mitochondria and is converted to lactate 22 . The Warburg effect might be advantageous to tumour cells for several reasons: enhanced production of glycolytic intermediaries supports macromolecular synthesis; generation of reducing equivalents, such as NAD+ that serves as a coenzyme for redox reactions; secretion of lactate can alter the microenvironment to promote tumour invasion and escape from immune cells; and glycolytic metabolism enables adaptation to low oxygen levels in hypoxic areas of the tumour [23] [24] [25] [26] . In brain tumour cells, the Warburg effect is controlled at several levels, including regulation by the PI3K/AKT/mTOR pathway, via BRAF activation, and through MYC induction (FIG. 1) . For example, phosphorylated AKT enhances glycolysis by increasing the expression of glucose transporters and by activating glycolytic enzymes, such as hexokinase-2 (HK2) and phosphofructokinase-1 (PFK1) [27] [28] [29] . Similarly, activated mTORC1 increases glucose metabolism and glyco lytic gene expression by regulating MYC activity in type-three EGFR mutant (EGFRvIII)-driven GBMs 30 . In addition, MYC and BRAF V600E can stimulate the transcription networks related to glycolysis, including those controlling the expression of glucose transporters and glycolytic enzymes [31] [32] [33] . By contrast, p53 can nega tively regulate the expression of glycolytic enzymes and glucose transporters 34 , and is frequently mutated in many types of brain cancer, including astrocytic tumours and medulloblastomas (TABLE 1) . Thus, glucose metabolism is a very attractive target for imaging of brain tumours.
Interestingly, many of the glycolytic enzyme isoforms that are preferentially expressed in proliferating cells during brain development are also expressed in brain tumours. For example, HK2 (which phosphorylates glucose to produce glucose-6-phosphate) and pyruvate kinase M2 (PKM2; which converts phosphoenolpyruvate to pyruvate) are expressed in the embryonic, but not the adult, brain [35] [36] [37] . Some brain tumours, such as GBMs and medulloblastomas, preferentially express HK2 and PKM2 isoforms -rather than HK1 and PKM1 (REFS 35, (37) (38) (39) (40) (41) (42) . Witney and colleagues 43 have reported the development of a 11 C-labelled PET-imaging probe specific for PKM2, which is based on a class of N,N-diarylsulfonamides (DASA) that are known to promote PKM2 tetramer formation (FIG. 1) . The predominantly intratumour accumulation of this probe, termed 11 C-DASA-23, was demonstrated in orthotopic animal models of GBM, corresponding to tumour-exclusive PKM2 expression 43 . 18 F-FDG-PET imaging was one of the earliest tools used to measure the location of glucose utilization in the brain. 18 F-FDG, like glucose, enters the cell via glucose transporters and is phosphorylated by hexokinase to form 2-[ 18 F]fluoro-2-deoxy-d-glucose-6-phosphate. This intermediate is unable to be further catabolized, and becomes trapped in the cell; therefore, its accumulation rate is a measure of glucose uptake [44] [45] [46] . In the imaging of gliomas, however, 18 F-FDG-PET has poor tumour-to-background contrast owing to the generally high levels of glucose uptake in the normal brain (FIG. 3) .
18
F-FDG-PET also has limited specificity in distinguishing between tumour and nonmalignant processes, including infection and inflammation 47 . Using 13 C-labelled glucose as a tracer, MRS can be used to monitor glucose metabolism in patients with glioma, and in animal models of this disease. The metabolic conversion of the administered metabolite can be measured by simultaneously quantifying, for example, the disappearance of 13 C-glucose and the appearance of 13 C in metabolic products, such as lactate or pyruvate. Using this technique, glycolysis in tumour specimens from animal models and from patients can be evaluated ex vivo, after being exposed to 13 C-glucose immediately before resection 22, 48 . Intriguingly, in mice orthotopically implanted with GBM cells derived directly from patients, infusion of 13 C-labelled glucose before tumour resection and subsequent MRS analysis of tumour specimens revealed entry of glucose-derived carbon into the TCA cycle, with lower generation of 13 C-lactate than expected 48 . 13 C is difficult to image using MRS owing to the low natural abundance (approximately 1%) and unfavourable gyromagnetic ratio of this carbon isotope, both of which result in low signal-to-noise ratios 49 . To overcome these limitations, 13 C-enriched probes can be 'hyperpolarized' by exposure to microwaves at extremely low temperatures before tracer administration, using a technique known as dynamic nuclear polarization. This approach alters the Boltzmann distribution of 13 C and can increase the sensitivity of detection using MRS by more than 10,000-fold 50 . The probe must be infused into the patient or model organism immediately before MRS analysis because 13 C-labelled probes remain hyperpolarized for only a very short period of time. The conversion of hyperpolarized [1- Red arrows depict common oncogenic signalling pathways in brain tumours, such as those involving activation of PI3K, AKT, mTOR and MYC, and those influenced by inactivating alterations in p53, which affect various aspects of glycolysis -generally increasing the glycolytic flux. PET tracers relating to this pathway are highlighted in green, and magnetic resonance spectroscopy (MRS) tracers in red. The two main substrates involved in glycolysis and related pathways that can be labelled for use as clinical imaging tracers are glucose and pyruvate (yellow ovals). Glucose analogues can be used for PET imaging (
F-FDG) or for MRS (
13 C-labelled glucose); greater uptake of these tracers in cancer cells, owing to the generally increased glycolytic flux in tumours compared with normal tissues, forms the basis of these imaging modalities. MRS can also be used to detect differences in the metabolism of 'hyperpolarized' 13 C-pyruvate to 13 C-lactate (as a result of the Warburg effect) between tumour and nonmalignant tissues. Hyperpolarization can increase sensitivity of molecular detection by more than 10,000-fold, and refers to enhancement of 13 C nuclear spin polarization by exposure of the tracer to microwaves at extremely low temperatures immediately before administration 50 . The expression levels of pyruvate kinase M2, the predominant form of pyruvate kinase expressed in tumour cells, can be interrogated using has been most extensively characterized using in vivo hyperpolarized- 13 C MRS, including a first-in-human study of this approach in patients with cancer 51 . With regard to glioma, hyperpolarized-13 C MRS studies have been conducted in animal models. For example, in rats, the generation of [1- 13 C]lactate from [1-13 C]pyruvate was detected in glioma xenografts in vivo, but not in nontumour brain tissues. The enhanced sensitivity of MRS for the detection of hyperpolarized tracers holds considerable promise in evaluating glycolysis and other meta bolic changes in patients with glioma. Moreover, the development of high-field 7T MRI has now expanded the capabilities of MRS, including techniques that leverage the chemical exchange saturation transfer (CEST) effect 52 , as well as 23 Na and 31 P spectroscopy 53, 54 . In contrast to 3T-field-strength MRS, at which the resonances of glutamate undergo strong coupling and overlap with glutamine and γ-aminobutyric acid (GABA) peaks, localized 1 H-MRS at 7T can be used to reproducibly measure cortical GABA and glutamate concentrations by enabling better resolution of these resonance peaks 55 . Moreover, the rate of ATP synthesis in the human brain can be quantified, and extracellular versus intracellular pH can be differentiated using 31 P MRS 56 . The spectrum of metabolic imaging studies might be further expanded by spectroscopic techniques with enhanced physiological and functional information based on CEST contrast. CEST is a sensitivity enhancement mechanism by which low concentrations of solutes containing exchangeable protons that have different resonance frequencies from those of bulk water protons can be selectively saturated with radiofrequency energy and visualized indirectly using the water signal, which is attenuated by the transfer of the saturated exchangable protons 52 . In models of GBM, amide and hydroxyl protons from different amino acids, proteins and other molecules have been assessed using this contrast technique to image glucose accumulation (an approach termed 'gluco CEST'), in order to detect early tumour responses to treatment [57] [58] [59] . Finally, combined PET-MRI systems are increasingly enabling a multi parametric approach to the non-invasive characterization of brain tumours 54, 60 ; further studies are needed to determine how this approach can be optimized and leveraged in clinical settings.
Imaging of IDH-mutant gliomas
IDH enzymes can convert isocitrate to α-ketoglutarate (α-KG), which can be used to generate reducing equivalents that are integral to ATP production and other metabolic processes (FIG. 2) . Human cells can express three isoforms of IDH: IDH1, IDH2, and IDH3. IDH1 is present in the cytosol, whereas IDH2 and IDH3 are mitochondrial proteins. Cancer-associated mutations in IDH1 and IDH2 are generally heterozygous and missense 13 . IDH1 is the most commonly mutated isoform in gliomas (>90% of IDH mutations affect IDH1), and mutations involve the catalytic-site arginine residue at position 132, resulting in substitution of this residue with histidine (R132H) 13 ; IDH2 mutations are rarely detected in gliomas 13 . IDH mutations result in the production of the metabolite d-2-hydroxyglutarate (d-2HG) by these enzymes (FIG. 2) .
Preclinical studies have revealed that d-2HG production by mutant IDH enzymes results in the transformation of immortalized human astrocytes, with a mechanism of oncogenesis that is related to the structural similarity of d-2HG to that of α-KG [61] [62] [63] [64] . α-KG serves as a critical cofactor for dioxygenase enzymes that regulate various cellular functions, including histone and DNA demethylation. d-2HG can inhibit the function of many of these enzymes, resulting in both DNA hypermethylation at CpG islands (that is, the G-CIMP epigenetic profile) and histone hypermethylation [65] [66] [67] [68] . Because d-2HG is produced in IDH1/2-mutant gliomas, but not in wild-type gliomas, this metabolite could serve as a biomarker for the diagnosis, treatment, and surveillance of these tumours via non-invasive ima ging. The use of in vivo MRS for the detection and quantification of d-2HG has been demonstrated in patients with IDH1/2-mutant gliomas [69] [70] [71] . The proximity of the d-2HG resonance peak to the glutamine, glutamate, and N-acetylaspartate (NAA) resonance peaks is one of the challenges in detecting the activity of mutant IDH1/2 using MRS 72 . This issue requires optimization of MRS protocols, using techniques such as 2D correlation spectroscopy or J-difference spectroscopy, to enable differentiation of the overlapping metabolite resonance peaks 69, 70 . Using these techniques, d-2HG can be detected at low milli molar concentrations (1.7-8.9 mM) in IDH1/2-mutant, but not in IDH1/2-wild-type, gliomas 69, 70 . Furthermore, the detection of d-2HG in vivo using MRS is correlated with a better prognosis, compared with that of patients in whom this metabolite is not detected, mirroring previously reported associations between IDH status determined by NGS and patient outcomes 13, 73, 74 . The MRS-based detection of d-2HG has high specificity in the assessment of IDH1/2 mutation status. The sensitivity of this approach, however, depend on the tumour size and cellularity, and can be as low as 8% for small tumours (defined as <3.4 ml in volume) compared with 91% for larger tumours (>8 ml in volume) 75 . In addition, hyperpolarized-13 C MRS might be harnessed to probe for the enzymatic function of mutant IDH1/2 in vivo 76 . For example, the conversion of (FIG. 2) can be detected in rats bearing IDH1-mutant, but not IDH1-wild-type, GBM xenografts using MRS 76 . This technique remains to be translated into the clinic; however, as the only imaging modality with specificity for detection of IDH mutation status, in vivo MRS (with or without hyperpolarization) represents an exciting foray into the use of a pharmacodynamic biomarker.
Imaging amino acid metabolism
Altered metabolism of many amino acids including glutamine, glutamate, methionine, aspartate, and tyrosine is often observed in brain tumours. The mechanisms by which brain tumour oncogenes reprogramme amino acid metabolism are only beginning to emerge. In the following sections, we outline how our current understanding of metabolic reprogramming can be exploited for assessment of disease using non-invasive imaging modalities. Nature Reviews | Clinical Oncology a b Glutamate. Glutamate and glutamine form vital metabolic connections between neurons and glial cells. In neurons, glutamine is metabolized to glutamate, which is an excitatory amino acid neurotransmitter released at synaptic terminals. After synaptic transmission, glutamate is taken up by astrocytes and is metabolized to glutamine, which is then recycled back to neurons for the synthesis of glutamate. Consequently, both glutamate and glutamine are abundant metabolites in the brain. Owing to the structural similarities between glutamine and glutamate, both of these amino acids produce similar MRS spectra and, therefore, are usually evaluated collectively. Of note, many primary brain tumours including gliomas, meningiomas, and medulloblastomas have altered levels of both amino acids [77] [78] [79] [80] . Additionally, tumour cells exchange glutamate for cysteine via the cysteine-glutamate antiporter termed 'system X c −' , which facilitates the production of glutathione -an important antioxidant and cofactor -from cysteine. PET imaging of glutamate exchange via system X c − can be achieved using (4S)-4-(3-[
18 F]fluoropropyl)-l-glutamate ( 18 F-FSPG) as a tracer 81, 82 (FIG. 2) . The X c − antiporter is expressed in GBM cells, and its expression is correlated with tumour invasion and poor patient outcomes 83, 84 . Thus, PET imaging of glutamate exchange with cysteine could potentially be useful in the analysis of brain tumours.
Glutamine. Glutamine is the most-abundant amino acid in the plasma, and many c ancers, including brain tumours, display increased cellu lar glutamine uptake and metabolism 85, 86 . Glutamine is metabolized by the enzyme glutaminase to form glutamate, which in turn can be metabolized by glutamate dehydrogenase to form α-KG; α-KG can enter the TCA cycle, and thus serves as a crucial contributor to anaplerosis and energy production 85, 87, 88 (FIG. 2) . In brain tumours, MYC, p53, and the PI3K/AKT/ mTOR pathways are involved in the regulation of glutamine metabolism. Amplification or activation of MYC is common in Group 3 and Group 4 medulloblastomas, as well as in histone H3 G34R/V-mutant paediatric GBMs (TABLE 1) . MYC regulates glutamine metabolism by increasing the expression of the glutamine transporter neutral amino acid transporter B(0) and glutaminase [89] [90] [91] [92] (FIG. 2) . Along similar lines, activation of mTOR stimulates glutamine metabolism by increasing the activity of glutamate dehydrogenase, whereas p53 directly regulates the transcription of glutaminase 93, 94 . In orthotopic mouse models of GBM with alterations in the PI3K pathway, however, MRS analysis of the tumours after infusion of 13 C-glutamine has revealed high levels of glutamine uptake, but limited glutamine metabolism via the TCA cycle 48 . Interestingly, in preclinical models, GBM cells use nitrogen derived from glutamine for nucleotide production -for example, via generation of intermediates, such as 5-aminoimidazole-4-carboxamide ribotide and inositol monophosphate, used in purine biosynthesis 95 . Thus, GBM cells have enhanced glutamine uptake, which might contribute to nucleotide synthesis; however, how glutamine is metabolized in tumour cells in patients' needs further elucidation.
Non-invasive in vivo measurement of glutamine uptake can be achieved in patients with glioma using (2S,4R)-4-[ F-FGln uptake is often increased in gliomas compared with normal brain tissues 86 , enabling clear delineation of the tumour using PET (FIG. 4) . Moreover, marked reductions in 18 F-FGln uptake have been observed following chemoradiotherapy, and were correlated with a reduced tumour burden 86 . Uptake of PET imaging compounds in gliomas can depend on the integrity of the blood-brain barrier (BBB) 96 . Findings from animal models and a small cohort of patients with glioma indicate that uptake of 18 F-FGln might not directly depend on disruption of the BBB, but this finding requires further validation in larger patient cohorts 86 . Furthermore, high 18 F-FGln uptake in highgrade gliomas (FIG. 4) can be used to distinguish patients with progressive disease from those with stable low-grade disease, who have minimal or no 18 F-FGln-PET avidity 86 . By contrast, 18 F-FDG-PET and conventional MRI do not offer this opportunity 97 , making metabolic imaging with 18 F-FGln-PET a potentially valuable clinical tool in the management of patients with glioma.
Methionine. Diverse pathways involved in cellular biosynthetic and homeostatic processes use substrates derived from carbon units donated from specific amino acids, termed one-carbon metabolism 98 ; methionine is a key component of this processes (FIG. 2) . In addition to protein synthesis, methionine can be used in other cellular processes, such as nucleotide biosynthesis and the synthesis of S-adenosylmethionine (SAM), which acts as a methyl donor for many reactions, including DNA and histone methylation 99 . Transport of Nature Reviews | Clinical Oncology a b radio labelled methionine into tumour cells does not depend on, but might be enhanced by, BBB disruption 100,101 . 11 C-methionine is one of the best-studied amino acid tracers for use in PET imaging of primary brain tumours (FIG. 5) , although the short half-life of 11 C (20 mins) limits the availability of this modality to centres with an on-site cyclotron 102 . In comparison with normal tissues, 11 C-methionine uptake is increased in malignant cells, including gliomas (FIG. 5) . The relationship between the genetic landscape of brain tumours and 11 C-methionine uptake on PET imaging is not known.
11 C-methionine can, however, be useful in detecting tumours, in assessing treatment response, and in predicting disease recurrence (see 'Metabolic imaging in patient care' section).
Aspartate. Characteristic chemical shifts can be visualized in gliomas using 1 H-MRS, including a decrease in NAA levels compared with normal brain tissue (FIG. 6) . NAA is an abundant metabolite in the normal brain and is synthesized mainly in neuronal mitochondria from aspartate and acetyl-CoA 103 . The exact function of this compound in the brain remains controversial; nevertheless, owing to the high abundance of NAA in the brain (second only to glutamate, among amino acids) and ease of detection on 1 H-MRS, levels of this metabolite are extensively used as an indicator of neuronal damage in various CNS pathologies 104, 105 . The detectable decrease in NAA levels in glioma might be attributable to reduced expression of enzymes involved in NAA biosynthesis (such as l-aspartate N-acetyltransferase) in tumour cells, in addition to a reduction in the number of untransformed neuronal cells owing to the invasive nature of many brain tumours 106, 107 . 1 H-MRS can be useful in diagnosis, in assessing treatment response, and in helping in the molecular subgrouping of medulloblastomas, as discussed in later sections of this Review.
Other amino acids. Multiple other radiolabelled amino acid analogues have been used in imaging studies of primary gliomas. O-(2-[
18 F]fluoroethyl)-l-tyrosine ( 18 F-FET) uptake on PET imaging primarily measures the amino acid transport rate, which is enhanced in malignancies, owing to increases in cellular demand for amino acids. This radiolabelled tracer is neither incorporated into proteins nor metabolized within the cell, and accumulates in tumour tissue in a largely unaltered form 108 .
18
F-FET-PET has been widely studied in patients with brain tumours, with increased tracer uptake demonstrated in studies principally including patients with low-grade or malignant gliomas, but also those with haemangioblastomas, or with brain metastases from lung or breast cancers, or melanoma 109 . 18 F-FET is licensed in many countries as a radiopharmaceutical agent for the diagnosis of human brain tumours. In a meta-analysis of 13 studies, nine of which were focused on determining the optimal tumour-to-background 18 F-FET-PET ratios for the initial diagnosis of brain glioma, a mean ratio of at least 1.7 and maximum ratio of at least 2.1 had the best diagnostic accuracy 109 . 18 F-FET uptake was markedly higher in oligodendroglial versus astrocytic tumours, and in tumours with 1p/19q co-deletion compared with tumours without these chromo somal aberrations 110 . Furthermore, 18 F-FET showed characteristic time-activity curves in IDH1/2-mutant gliomas compared with IDH1/2-wild-type gliomas 111 . These data need to be confirmed in larger patient cohorts, and the biology underlying these observations requires further elucidation. Nevertheless, these findings suggest a potential non-invasive method for evaluating patients particularly those with nonresectable tumours (such as those in highly eloquent areas) in whom a risk-adapted management approach could be adopted if a molecularly favourable 1p/19q co-deleted tumour -with anticipated chemosensitivity -is suspected 110 . Nature Reviews | Clinical Oncology C-methionine axial PET scan in a patient with glioblastoma reveals a focus of high tracer uptake (arrow) inferior to the surgical cavity (denoted by black outline). b | Contemporaneous T1-weighted, gadoliniumenhanced MRI does not reveal any residual enhancing abnormality in the corresponding area of high PET tracer uptake (arrow). c | 6 months after treatment, however, an enhancing tumour recurrence is noted on an axial MRI scan, in the area initially identified using 11 C-methionine PET (arrow). This example demonstrates the value of metabolic imaging in assessing the extent of residual disease after tumour resection and the potential to target such regions with radiotherapy (or otherwise escalate anticancer therapy in patients with residual disease).
3,4-dihydroxy-6-[
18 F]fluoro-l-phenylalanine ( 18 F-FDOPA) uptake on PET scans also reflect cellular amino acid transport in general, but is additionally the substrate of aromatic amino acid decarboxylase that is integral to the nigrostriatal dopaminergic system as a normal physiological feature of the brain. The increased uptake of 18 F-FDOPA in brain neoplasms is a function of the pathologically increased expression of the large neutral amino acid transport system in the tumour compared with the nonmalignant brain tissues, and dopaminergic antagonists have been shown to inhibit the proliferation of GBM stem cells 112 . High rates of 18 F-FDOPA uptake are, however, observed in the nonmalignant basal ganglia tissues, thus complicating analysis of tumours located in this region 108 . Among PET tracers, l-[1-
11 C]leucine most directly reflects cellular protein synthesis, although its uptake is also affected by alterations in the amino acid transport system in the brain 113 . Taurine (an organic acid derived from cysteine) and creatine (a nitrogenous organic acid derived from glycine and arginine) are other aminoacid-related metabolites that are commonly investigated using 1 H-MRS for the analysis of brain tumours 114 . These metabolites, although not considered direct surrogate indicators of amino acid metabolism, are used to clini cally evaluate brain tumours, as discussed in later sections of this Review.
Imaging fatty acid metabolism
Cancer cells undertake both de novo fatty acid synthesis and enhanced fatty acid oxidation 3 . The fatty acids synthesized can serve as precursors for the generation of many biomolecules, including phospholipids, sphingolipids, prostaglandin, and cholesterol esters. Choline is an essential nutrient that is required for synthesis of phospho lipids and the neurotransmitter acetylcholine, and levels of this metabolite are often increased in cancer cells, which might reflect increased rates of cell membrane turnover 4 . Using 1 H-MRS and 31 P-MRS, the increased levels of choline-containing metabolites in brain tumours can be non-invasively detected in patients 4 (FIG. 6 ). An elevated total choline signal can be used clinically for the primary diagnosis of low-grade and high-grade glioma, and the detection of recurrent glioma versus tumour necrosis following radiation therapy 115, 116 . Oncogenic proteins, such as the activated EGFR, can control fatty acid synthesis through activation of the PI3K/ AKT/mTOR pathway, which results in stabilization of enzymes that regulate lipogenesis, such as sterol regulatory element-binding protein-1 (SREBP-1) 117 (FIG. 2) . Moreover, PI3K-pathway activation in gliomas results in elevated levels of acetyl-CoA, which is the principal carbon donor for fatty acid synthesis [118] [119] [120] . Acetyl-CoA can be derived from pyruvate and can also be synthesized from acetate by the enzyme acetyl-CoA synthetase (ACS) 121, 122 . GBMs often have increased expression of ACS, compared with that of normal brain tissues, which results in expanded pools of acetyl-CoA that could be used for both oxidation within the TCA cycle and lipid synthesis 123 (FIG. 2) . The findings of ex vivo MRS studies using 13 C-acetate suggest that acetate-derived acetyl-CoA is metabolized via mitochondrial oxidation in orthotopic brain tumour models and in patients with GBM 
Molecular imaging of other processes
Cell proliferation. Additional key components of tumorigenesis driven by alterations in tumour metabolism can be directly assessed using molecular imaging. For example, the altered metabolism observed in tumours supports rapid cellular proliferation; compared with nonmalignant proliferating cells, tumour cells have increased levels of thymidine kinase (TK-1) and, therefore, radio labelled nucleoside analogues of thymidine, such as 3ʹ-deoxy-3ʹ[
18 F]fluorothymidine ( 18 F-FLT), are transported into cells, phosphorylated by TK-1, and trapped intracellularly at an increased rate in tumours [125] [126] [127] . This process is dependent on disruption of the BBB within tumours, as transport of 18 F-FLT across the intact BBB is slow; thus, 18 F-FLT-PET is not as useful for detecting non-enhancing primary brain tumours with an intact BBB (such as lowgrade gliomas) 127 . 18 F-FLT-PET correlates with levels of TK-1, but not with those of general proliferation markers, including proliferating cell nuclear antigen and Ki67 . TK-1 regulates the thymidine salvage pathway, hence 18 F-FLT-PET might be an indirect measure of the activity of this pathway. Thus, 18 F-FLT-PET might be of limited utility in highly proliferative tumours; this limited utility might reflect a dependence of highly proliferative tumours on both de novo thymidine synth esis and the thymidine salvage pathway to support nucleotide synthesis and, therefore, cell proliferation [128] [129] [130] . Hypoxia. Hypoxia is another key feature of rapidly growing tumours, and promotes adaptive responses, such as angiogenesis, upregulated glucose metabolism, and optimized mitochondrial respiration, which confer a survival advantage to hypoxic tumour cells 131 . Thus, hypoxia is an important predictor of resistance to antineoplastic treatments, including systemic therapy and radiotherapy, and can be imaged using a number of PET tracers, of which [
18 F]fluoromisonodazole ( 18 F-FMISO) is the most extensively studied 132 . Importantly, 18 F-FMISO-PET enables spatial delineation of hypoxic regions of brain tumours independently of BBB disruption and tumour perfusion 133 .
Angiogenesis. Angiogenesis, a process closely related to hypoxia, is another hallmark of tumour growth, and the resulting abnormal tumour vasculature contributes to a hostile tumour microenvironment, characterized by low oxygen tension and high interstitial fluid pressure, which selects for a more malignant phenotype 134 . α v β 3 -integrin, a target structure for molecular imaging, is highly expressed on activated endothelial cells during angiogenesis 135 . Thus, various ligands based on the tripeptide Arg-Gly-Asp (RGD), which binds with high affinity to α v β 3 -integrin, have been developed as PET tracers for the assessment of angiogenesis 135 . For example, the glycosylated cyclic penta peptide 18 F-galacto-RGD has been successfully applied in the assessment of patients with malignant gliomas, with high uptake detected in regions of rapid cell proliferation and tumour infiltration, compared with low uptake in the normal brain 136 . The non-invasive detection of tumour targets is a promising tool for treatment planning before, and for disease monitoring during or after, individualized therapy targeting this integrin, and for potential demonstration of receptor occupancy by 18 F-galacto-RGD-PET that could also potentially be used to assess the most efficient drug dose for individual patients 136 .
Metabolic imaging in patient care
In the previous sections of this Review, we have examined how different genetic alterations in primary brain tumours can reprogramme metabolism, and how some of these phenotypes can be leveraged for non-invasive imaging assessments of tumours in preclinical animal models and in patients. In the following sections, we examine the potential for metabolic imaging to be assimilated into routine clinical care.
Tumour delineation for local therapy
Metabolic imaging of brain tumours can provide greater accuracy when planning biopsy sampling and/or tumour resection, and during radiotherapy target delineation; for example, the extent of tumour infiltration can be better defined using 11 C-methionine PET compared with conventional imaging modalities, such as T1-weighted gadolinium-enhanced, or T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI, and can identify aggressive tumour regions with high risk of recurrence 137 . Indeed, the use of amino-acid-based PET can improve the identification of the most biologically aggressive components of heterogeneous low-grade and highgrade gliomas -information that could dictate subsequent therapy and also reduces the risk of an incomplete resection, particularly for tumours located near eloquent regions of the brain [138] [139] [140] [141] . The use of multiple imaging modalities, including multi-voxel 1 H-MRS and diffusion and/or perfusion MRI, can also help in distinguishing between heterogeneous regions of dense tumour infiltration, areas of oedema with admixed tumour cells, and oedema in regions not infiltrated by the tumour 142 . PETbased analyses of tumour volumes using various amino acid tracers has revealed that gliomas often extend beyond the contrast-enhancing volume observed on conventional MRI scans by 2.0-3.5 cm (depending on the tracer), and amino acid PET enables identification of the tumour extent within regions of nonspecific T2-weighted FLAIR abnormality [143] [144] [145] (FIG. 5) .
Prognostication and response prediction
In patients with low-grade glioma, 18 F-FET-PET timeactivity curves have been shown to be correlated with malignant progression and survival outcomes, suggesting a role of this imaging modality in prognostication 45, 46, [146] [147] [148] . Moreover, the volume of 18 F-FET and 11 C-methionine uptake on PET scans before chemoradiotherapy has been shown to be highly predictive of patient outcome 149, 150 . Use of 1 H-MRS for the prediction of survival outcomes has been evaluated in multiple studies in populations of adult and paediatric patients with brain tumours; worse outcomes were observed in patients with an elevated tumour choline-to-NAA ratio before treatment, or before adjuvant chemoradiotherapy 151, 152 . Patients with IDH1/2-mutant gliomas have a better prognosis that those with IDH-wild-type tumours, thus d-2HG levels might also serve as a prognostic indicator 73, 153 , and could potentially be used to monitor and predict the outcomes of targeted therapies, particularly inhibitors of mutant IDH.
Assessing treatment response
A variety of metabolic changes in both the tumour and tumour microenvironment are observed following cytotoxic, radiation, and antiangiogenic therapies; many can be detected using MRS and this approach might form the basis of non-invasive assessments of responses to treatment. For example, decreases in the MRS choline-to-water ratio in patients with low-grade gliomas treated with temozolomide chemotherapy parallel reductions in tumour volume 154, 155 . Serial MRS imaging of patients undergoing adjuvant radiation treatment for malignant gliomas reveal that a decline in the mean tumour choline-to-NAA ratio, and early changes of lactate-to-NAA and choline-to-creatine ratios during treatment are predictive of outcome 156 . These findings might open opportunities for adaptive, response-based radiation treatment. Using 31 P-MRS and/or 1 H-MRS, increased hypoxia and impaired oxidative metabolism can be detected in patients with recurrent GBM treated with the anti-VEGF antibody bevacizumab 157 . Detection of these alterations in the tumour microenvironment might be correlated with clini cal prognosis and outcome, and thus could potentially be used as an early biomarker of therapeutic efficacy in order to inform the decision to continue therapy. Following the treatment of patients with recurrent GBM using the VEGFR tyrosine kinase inhibitor cediranib, a direct meta bolic effect and antitumour response can be observed with serial MRS assessments, as indicated by a substantial increase in the NAA-to-choline ratio after 28 days; this response might predict 6-month overall survival 158 .
Findings of studies incorporating serial 18 F-FET and 11 C-methionine PET imaging have demonstrated that a reduction in amino acid uptake during the course of therapy is a marker of tumour response and is correlated with clinical outcome, and that these PET approaches are more informative than T1-weighted gadoliniumenhanced MRI 148, 159 . Intriguingly, data from a subset of patients with IDH1/2-mutant glioma who received multiple MRS scans while undergoing active treatment indicate that a decline in d-2HG levels mirrored treatment response, as defined by changes in tumour volumes or Karnofsky performance score 75, 153 . As d-2HG levels are, however, related to tumour size, further studies are needed before this technique can be applied clinically as a biomarker assessment of treatment response, or to predict early disease progression 75 .
Monitoring of resistance or progression
The emergence of treatment resistance and/or tumour recurrence is a major cause of morbidity and mortality in patients with high-grade brain tumours. Metabolic changes that occur during the emergence of treatment resistance are poorly understood. Nevertheless, both glucose and amino acid metabolism undergo reprogramming during the emergence of resistance to radiation and chemotherapy 93, 160, 161 . Recurrent GBMs are hypermutated and harbour many new driver mutations, predominantly in the PI3K/AKT/mTOR pathway 161 . Both glucose and amino acid metabolism are directly modulated by this pathway 93 (FIGS 1,2) and, therefore, would be expected to undergo metabolic reprogramming in recurrent GBM. Along these lines, glutamine metabolism is enhanced in preclini cal models of treatment-resistant glioma 162 . Thus, non-invasive metabolic imaging has the potential to detect the onset of treatment resistance at an early stage and thereby inform timely alterations in clinical care, warranting further clinical studies of this strategy.
Pseudoprogression is a major clinical challenge in the non-invasive, imaging-based detection of tumour recurrence in patients. Pseudoprogression is defined as treatment-related changes, such as tumour necrosis and inflammation, that mimic tumour recurrence on conventional MRI 163 . Alterations in metabolism that are seen at tumour recurrence can be leveraged to differentiate relapse from pseudoprogression. For example, metabolic imaging with PET and amino acid tracers has been demonstrated to help in distinguishing BBB alterations and contrast enhancement observed after chemo radiation, which are both features of pseudoprogression, from true disease progression [164] [165] [166] [167] [168] . Both static and dynamic 18 F-FET-PET parameters (such as mean tumour-to-brain uptake ratio ≥2.0, and time to peak <45 mins) differentiate glioma progression or recurrence with greater accuracy than conventional MRI parameters 169 . In addition 11 C-methionine PET (FIG. 5) and, to a lesser extent, 18 F-FDOPA-PET can enable identification of tumour recurrence with greater sensitivity and specificity than conventional MRI; use of these PET techniques has been reported to influence the approach to care in 41-50% of patients evaluated 102, 125, 170 . 1 H-MRS has also been applied to differentiate between tumour recurrence and radiation necrosis in adult and paediatric populations, with increased choline signals (choline-to-creatine or choline-to-NAA ratios) suggesting tumour recurrence (FIG. 6) , whereas reduced choline levels -and possibly elevated lipid and lactate signals -suggesting radi ation necrosis 116, 171, 172 . The use of MRS might not enable reliable distinction of these phenomena in instances of a mixed area of viable tumour and radiation necrosis; however, this modality is often more informative than conventional MRI, and can provide early information on tumour metabolism before the appearance of morphological or volumetric changes that are visible on conventional MRI 115, 173 .
Molecular subgrouping
The non-invasive identification of clinically relevant (prognostic or predictive) molecular tumour subgroups is another potential application of metabolic ima ging. Imaging of d-2HG is a prime example, as IDH1/2 mutations that result in generations of this metabolite are charac teristic of low-grade gliomas and proneural secondary of GBM (TABLE 1) . Similarly, the use of MRS enables differentiation between SHH and Group 3/4 medulloblastomas. Specifically, SHH medulloblastomas have high levels of choline and lipids, but low creatine and taurine levels 174, 175 . By contrast, Group 3/4 medulloblastomas are characterized by higher taurine levels, but lower levels of lipids and creatine 175 . How SHH signalling and the oncogenes that drive Group 3/4 medulloblastoma impart these metabolic phenotypes is not known. Activation of MYC in Group 3 medulloblastomas is associ ated with a poor prognosis; as discussed above, MYC reprogrammes glutamine metabolism, and the meta bolic changes could potentially serve, in addition to glutamate levels, as a biomarker of more-aggressive disease. Indeed, glutamate abundance is a prognostic biomarker in patients with medullo blastoma 80 . In addition, a higher mean tumour-to-normal tissue ratio of 11 C-methionine uptake on PET scans has been observed in grade II-III oligo dendro glial tumours without 1p/19q co-deletion, compared with those in 1p/19q co-deleted tumours. The basis for these and other molecular phenotypes in brain cancers are the focus of ongoing research 176 .
Conclusions
As we make important strides towards understanding the molecular basis of brain tumours, further work is needed to develop non-invasive tools for evaluating these alterations and integrating them into daily clinical practice. Altered cancer metabolism offers a unique window to integrate genomic information with advanced imaging modalities, and the field has progressed rapidly with novel techniques that have been successfully implemented for analysis of tumours in preclinical models and in patients. Additional work is needed, however, to standardize these metabolic imaging techniques for routine clinical use. In combination with other functional imaging modalities, these techniques might prove complementary to conventional MRI in characterizing tumour biology and metabolism, with the aim of informing patient management. Future studies based on oncogene-driven metabolic pathways might enhance diagnosis, prognostication, treatment, and surveillance of brain tumours, and ultimately improve patient outcomes.
